Show simple item record

dc.contributor.authorBaselga, J.
dc.contributor.authorGomez, P.
dc.contributor.authorGreil, R.
dc.contributor.authorBraga, S.
dc.contributor.authorCliment, M.
dc.contributor.authorWardley, A.
dc.contributor.authorKaufman, B.
dc.contributor.authorStemmer, S.
dc.contributor.authorPego, A.
dc.contributor.authorChan, Arlene
dc.contributor.authorGoeminne, J.
dc.contributor.authorGraas, M.
dc.contributor.authorKennedy, J.
dc.contributor.authorCiruelos, E.M.
dc.contributor.authorSchneeweiss, A.
dc.contributor.authorZubel, A.
dc.contributor.authorGroos, J.
dc.contributor.authorMelezinkova, H.
dc.contributor.authorAwada, A.
dc.date.accessioned2017-01-30T11:07:41Z
dc.date.available2017-01-30T11:07:41Z
dc.date.created2014-11-19T01:13:19Z
dc.date.issued2013
dc.identifier.citationBaselga, J. and Gomez, P. and Greil, R. and Braga, S. and Climent, M. and Wardley, A. and Kaufman, B. et al. 2013. Randomized Phase 11 Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatis Triple-Negative Breast Cancer. Journal of Clinical Oncology. 31 (20): pp. 2586-2593.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/8601
dc.publisherAmerican Society of Clinical Oncology
dc.titleRandomized Phase 11 Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatis Triple-Negative Breast Cancer
dc.typeJournal Article
dcterms.source.volume31
dcterms.source.number20
dcterms.source.startPage2586
dcterms.source.endPage2593
dcterms.source.issn0732 183X
dcterms.source.titleJournal of Clinical Oncology
curtin.accessStatusFulltext not available


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record